Third suggestive announcement on the resale of "13 Spike 02" corporate bonds
Release time:
2020-08-05
股票代码:600668 股票简称:尖峰集团 公告编号:临2017-030
债券简称:13尖峰01 债券代码:122227
债券简称:13尖峰02 债券代码:122344
浙江尖峰集团股份有限公司
关于“13尖峰02”公司债券回售的第三次提示性公告
本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏,并对其内容的真实性、准确性和完整性承担个别及连带责任。
重要提示:
● 回售代码:100934
● 回售简称:尖峰回售
● 回售价格:100元/张。
● 回售申报期:2017年10月13日至2017年10月19日。
● 回售款到账日:2017年11月20日
● 债券利率是否调整:不调整
特别提示:
1、根据《浙江尖峰集团股份有限公司公开发行公司债券(第二期)募集说明书》,发行人有权决定是否在本期债券存续期的第3年末上调本期债券后2年的票面利率。本期债券在存续期前3年票面利率为5.09%,在本期债券的第3年末,公司选择不调整本期债券票面利率,即本期债券后2年票面利率为5.09%并保持不变。
2、根据《浙江尖峰集团股份有限公司公开发行公司债券(第二期)募集说明书》设定的回售选择权,发行人发出关于是否上调本期债券票面利率及上调幅度的公告后,投资者有权选择将持有的本期债券全部或部分按面值回售给发行人,或选择继续持有本期债券。
3、 “13尖峰02”债券持有人,可按照本公告规定,在回售申报期对其所持有的全部或部分“13尖峰02”债券进行回售申报登记。本次回售申报期内不进行申报的,视为放弃回售选择权,继续持有本期债券并接受上述关于维持“13尖峰02”票面利率的决定。
4、“13尖峰02”债券持有人的回售申报一经确认后不能撤销,相应的债券将冻结交易,直至本次回售实施完毕后相应债券被注销。
5、本次回售等同于“13尖峰02”债券持有人于本期债券第3个计息年度付息日,以100元/张的价格卖出“13尖峰02”债券,请“13尖峰02”债券持有人慎重判断本次回售的风险。
6、本公告仅对“13尖峰02”债券持有人申报回售的有关事宜作简要说明,不构成对申报回售的建议,“13尖峰02”债券持有人欲了解本期债券回售的详细信息,请通过上海证券交易所网站(http://www.sse.com.cn)查阅相关文件。
7、本次回售资金发放日指公司向本次有效申报回售的“13尖峰02”债券持有人支付本金及当期利息之日,即2017年11月20日。
为保证发行人上调票面利率选择权和投资者回售选择权有关工作的顺利进行,现将有关事宜公告如下:
一、释义
|
发行人、公司、尖峰集团 |
指 |
浙江尖峰集团股份有限公司 |
|
13尖峰02、本期债券 |
指 |
浙江尖峰集团股份有限公司2013年公司债券(第二期) |
|
公司债券 |
指 |
公司依照法定程序发行、约定在一定期限还本付息的有价证券 |
|
本次回售 |
指 |
“13尖峰02”债券持有人可选择将其持有的全部或部分“13尖峰02”公司债券在本期债券第3个计息年付息日按面值回售给本公司 |
|
本次回售申报期 |
指 |
“13尖峰02”持有人可以申报本次回售的期间,即2017年10月13日至2017年10月19日 |
|
付息日 |
指 |
“13尖峰02”公司债券的利息每年支付一次,为债券存续期每年的11月20日(遇法定节假日或休息日,顺延至其后的第1个工作日;每次付息款项不另计利息) |
|
回售资金发放日 |
指 |
本公司向本次有效申报回售的“13尖峰02”持有人支付本金及当期利息之日,即“13尖峰02”债券存续期间第3个付息日,即2017年11月20日 |
|
上交所 |
指 |
上海证券交易所 |
|
登记机构 |
指 |
中国证券登记结算有限责任公司上海分公司 |
|
元 |
指 |
人民币元 |
二、本期债券基本情况
1、债券名称:浙江尖峰集团股份有限公司2013年公司债券(第二期)。
2、债券简称及代码:13尖峰02、122344
3、发行人:浙江尖峰集团股份有限公司
4、发行规模:人民币3亿元。
5、债券期限:本期债券的期限为5年(附第3年末发行人上调票面利率选择权和投资者回售选择权)。
6、债券利率或其确定方式:本期债券票面利率在债券存续期的前3年固定不变。如发行人行使上调票面利率选择权,未被回售部分债券存续期限后2年票面年利率为债券存续期限前3年票面年利率加上调基点,在债券存续期限后2年固定不变。如发行人未行使上调票面利率选择权,则未被回售部分债券在存续期限后2年票面利率仍维持原有票面利率不变。本期公司债券票面利率由发行人和保荐人(主承销商)通过市场询价协商确定。
7、发行人上调票面利率选择权:发行人有权决定是否在本期债券存续期的第3年末上调本期债券后2年的票面利率。发行人将于本期债券第3个计息年度付息日前的第30个交易日,在中国证监会指定的上市公司信息披露媒体上发布关于是否上调本期债券票面利率以及上调幅度的公告。若发行人未行使利率上调选择权,则本期公司债券后续期限票面利率仍维持原有票面利率不变。
8、投资者回售选择权:发行人发出关于是否上调本期债券票面利率及上调幅度的公告后,投资者有权选择将持有的本期债券全部或部分按面值回售给发行人。若投资者行使回售选择权,本期债券第3个计息年度付息日即为回售支付日,发行人将按照交易所和债券登记机构相关业务规则完成回售支付工作。
9、回售申报:自发行人发出关于是否上调本期债券票面利率及上调幅度的公告日起5个交易日内,债券持有人可通过指定方式进行回售申报。债券持有人的回售申报经确认后不能撤销,相应的公司债券份额将被冻结交易;回售申报期不进行申报的,则视为放弃回售选择权,继续持有本期债券并接受发行人关于是否上调本期债券票面利率及上调幅度的决定。
10、债券形式:实名制记账式公司债券。投资者认购的本期债券在债券登记机构开立的托管账户托管记载。本期债券发行结束后,债券持有人可按照有关主管机构的规定进行债券的转让、质押等操作。
11、还本付息方式:采用单利按年计息,不计复利。每年付息一次,到期一次还本,最后一期利息随本金的兑付一起支付。若债券持有人在第3年末行使回售选择权,回售部分债券的票面面值加第3年的利息在投资者回售支付日一起支付。
12、上市时间和地点:本期债券于2014年12月11日在上海证券交易所上市交易。
三、本期债券回售实施办法
1、回售代码:100934 回售简称:尖峰回售
2、回售申报期:2017年10月13日至2017年10月19日。
3、回售价格:人民币100元/张(不含利息)。以1,000元为一个回售单位,回售金额必须是1,000元的整数倍且不少于1,000元。
4、回售申报办法:投资者可选择将持有的债券全部或部分回售给发行人,在回售申报期内通过上海证券交易所交易系统进行回售申报,当日可以撤单,每日收市后回售申报一经确认,不能撤销。如果当日未能申报成功,或有未进行回售申报的债券余额,可于次日继续进行回售申报(限回售申报期内)。
5、选择回售的投资者须于回售申报期内进行登记,逾期未办理回售申报手续即视为投资者放弃回售,同意继续持有本期债券。
6、回售部分债券兑付日:2017年11月20日。发行人委托中国证券登记结算有限责任公司上海分公司为申报回售的债券持有人办理兑付。
7、风险提示:投资者选择回售等同于投资者以100元/张(不含利息)的价格卖出“13尖峰02”,投资者参与回售可能会带来损失,请“13尖峰02”债券持有人慎重判断本次回售的风险。
四、回售部分债券付款情况
1、回售资金到帐日:2017年11月20日。
2、回售部分债券享有2016年11月20日至2017年11月19日期间利息,票面年利率为5.09%。每手债券(面值人民币1,000元)派发利息为人民币50.90元(含税),扣税后个人投资者、证券投资基金债券持有人取得的实际每手债券派发利息为40.72元;扣税后非居民企业(包含QFII、RQFII)取得的实际每手债券派发利息为45.81元。
3、付款方式:发行人将依照中国证券登记结算有限责任公司上海分公司的登记结果对本期债券回售部分支付本金及利息,该回售资金通过中国证券登记结算有限责任公司上海分公司清算系统进入投资者开户的证券公司的登记公司备付金账户中,再由该证券公司在回售资金到帐日划付至投资者在该证券公司的资金账户中。
五、回售申报期间的交易
本期债券在回售申报期内将继续交易。回售部分债券在回售申报截止日收市后将被冻结。
六、回售价格
根据《浙江尖峰集团股份有限公司公开发行公司债券(第二期)募集说明书》的有关约定,回售价格为债券面值(100元/张)。
七、回售申报期
2017年10月13日至2017年10月19日
八、回售申报程序
1、申报回售的“13尖峰02”债券持有人应在2017年10月13日至2017年10月19日正常交易时间(9:30-11:30,13:00-15:00),通过上交所交易系统进行回售申报,申报代码为100934,申报方向为卖出,回售申报一经确认后不能撤销,相应的债券将被冻结交易,直至本次回售实施完毕后相应债券被注销。在回售资金发放日之前,如发生司法冻结或扣划等情形,债券持有人的该笔回售申报业务失效。
2、“13尖峰02”债券持有人可对其持有的全部或部分有权回售的债券申报回售。“13尖峰02”债券持有人在本次回售申报日不进行申报的,视为对回售选择权的无条件放弃。
3、对“13尖峰02”债券持有人的有效回售申报,公司将在本年度付息日(2017年11月20日)委托登记机构通过其资金清算系统进行清算交割。
九、回售实施时间安排
|
时间 |
工作内容 |
|
2017年10月9日 |
发布本次回售公告 |
|
2017年10月9日 |
发布是否调整票面利率的公告 |
|
2017年10月10日 |
发布本次回售的第一次提示性公告 |
|
2017年10月11日 |
发布本次回售的第二次提示性公告 |
|
2017年10月12日 |
发布本次回售的第三次提示性公告 |
|
2017年10月13日至2017年10月19日 |
本次回售申报期 |
|
2017年10月24日 |
发布本次回售申报情况的公告 |
|
2017年11月20日 |
发布关于回售实施结果的公告 |
|
2017年11月20日 |
回售资金到账日 |
十、风险提示及相关处理
1、本次回售等同于“13尖峰02”持有人于债券存续期间第3个计息年度付息日(2017年11月20日),以100元/张的价格(净价)卖出“13尖峰02”债券。请“13尖峰02”持有人对是否行使回售选择权进行慎重判断并作出独立决策,本公告不构成对本期债券持有人是否行使回售选择权的建议。
2、上交所对公司债券实行“净价交易,全价结算”,即“13尖峰02”按净价进行申报和成交,以成交价格和应计利息额之和作为结算价格。
十一、关于本次回售所付利息缴纳所得税的说明
(一)关于向个人投资者征收企业债券利息所得税的说明
根据《中华人民共和国个人所得税法》以及其他相关税收法规和文件的规定,本期债券个人投资者应缴纳公司债券个人利息收入所得税。本期债券利息个人所得税将由各兑付机构负责代扣代缴,并直接向各兑付机构所在地的税务部门缴付。本期债券的个人利息所得税征缴说明如下:
1、纳税人:本期债券的个人投资者;
2、征税对象:本期债券的利息所得;
3、征税税率:按利息额的20%征收;
4、征税环节:个人投资者在兑付机构领取利息时由兑付机构一次性扣除;
5、代扣代缴义务人:负责本期债券付息工作的各兑付机构。
6、本期债券利息税的征管部门:各兑付机构所在地的税务部门。
(二)关于向非居民企业征收企业债券利息所得税的说明
对于持有“13尖峰02”的合格境外机构投资者等非居民企业(其含义同《中华人民共和国企业所得税法》),根据2008年1月1日起施行的《中华人民共和国企业所得税法》及其实施条例、2009年1月1日起施行的《非居民企业所得税源泉扣缴管理暂行办法》(国税发[2009]3号)以及2009年1月23日发布的《关于中国居民企业向QFII支付股息、红利、利息代扣代缴企业所得税有关问题的通知》(国税函[2009]47号)等规定,非居民企业取得的发行人本期债券利息应当缴纳10%的企业所得税,中国证券登记结算有限责任公司上海分公司将按10%的税率代扣相关非居民企业上述企业所得税,在向非居民企业派发债券税后利息,将税款返还债券发行人,然后由债券发行人向当地税务部门缴纳。
十二、本期债券回售的相关机构
1、发行人:浙江尖峰集团股份有限公司
住所:浙江省金华市婺江东路88号
法定代表人:蒋晓萌
联系人:朱坚卫、周恒斌
联系电话:0579-82320582、82324699
传真:0579-82320582、82324699
2、主承销商:浙商证券股份有限公司
法定代表人:吴承根
住所:浙江省杭州市江干区五星路201号
联系人:华佳、马岩笑
联系电话:0571-87902082、87903124
传真:0571-87903239
3、托管人:中国证券登记结算有限责任公司上海分公司
地址:上海市陆家嘴东路166 号中国保险大厦3层
联系人:徐瑛
电话:021-68870114
传真:021-68875802
邮政编码:200120
特此公告。
浙江尖峰集团股份有限公司
董事会
2017年10月12日
More information
Pharmaceutical Company Established New Drug R & D Promotion Committee
Recently, the new drug research and development promotion committee of Jianfeng pharmaceutical company was formally established, which will be responsible for promoting the new drug research and development progress of pharmaceutical companies and subordinate enterprises, and coordinating the new drug research and development work of various departments and subordinate enterprises. The New Drug Promotion Committee is headed by Huang Jinlong, deputy general manager of the group and general manager of the pharmaceutical company, and Jiang Hong, deputy general manager of the pharmaceutical company, is headed by Pang Xiong, Shi Cunyuan, Xu Lizhen, Yu Jingjing, Zheng Kunwu, Feng Lixiang, Kang Litao, Li Qian, Wu Chonggui, Zhai Tsunami, Huang Fang and Tong Xiaojun. The committee has an office, and Shi Cunyuan is also the director of the office, responsible for the supervision, communication, and coordination of the company's new drug research and development projects. The main responsibilities of the new drug promotion committee include: organizing the establishment and improvement of the R & D project management system and relevant regulations of the pharmaceutical company; organizing the formulation of the development plan of the new drug R & D project of the pharmaceutical company and supervising the implementation; making decisions on project initiation and participating in project evaluation; supervising the management of new drug R & D of the pharmaceutical company and providing guidance; Responsible for the process management of new drug R & D projects and the promotion and coordination of new drug R & D; carry out the assessment of new drug research and development projects; issue the responsibility system assessment and task statement of new drug research and development projects; be responsible for solving major technical problems in the process of new drug research and development; be responsible for the research and improvement of the management mode of research and development projects of pharmaceutical companies; be responsible for the future trend analysis of new drug research and development projects; review the major scientific research achievements of pharmaceutical companies and put forward reward suggestions. Huang Jinlong said that the research and development of new drugs is an important foundation for the healthy development of the pharmaceutical industry and is a systematic project. Jianfeng Pharmaceutical has always attached great importance to the research and development of new drugs, but there is still a certain gap between the progress of research and development and the development process of the enterprise, and the lack of coordination in the research and development process also affects the progress and quality of new drug research and development to a certain extent. The purpose of the establishment of the New Drug Research and Development Promotion Committee is to solve the progress of new drug research and development, to find and solve problems in time, to implement more targeted, and to effectively integrate enterprise resources, improve the speed and quality of new drug research and development, and make good product reserves for the healthy development of pharmaceutical companies. (Reporter Ni Yingzhen)
2020
09-11
Jianfeng Pharmaceutical ranks among the top 100 Chinese pharmaceutical industries in 2019
On August 25, the "2019 Top 100 Series List of China's Pharmaceutical Industry" was released in Kunming. Zhejiang Jianfeng Pharmaceutical Company was shortlisted as one of the top 100 enterprises in China's pharmaceutical industry. The product Berunning (Olopatadine Hydrochloride Eye Drops) was selected as the "Most Growing Product Brand" of China's pharmaceutical industry ". The "Top 100 Pharmaceutical Industry Series List" was evaluated and released by Guangzhou Punctuation Pharmaceutical Information Co., Ltd., a subsidiary of the Southern Institute of Pharmaceutical Economics of the State Drug Administration, and is known as the "Oscar in Chinese Pharmaceutical Industry. Southern Institute is the earliest institution in China that specializes in pharmaceutical industry policy and market economy research, pharmaceutical market research, pharmaceutical economic data analysis and research, and pharmaceutical professional media publishing. It is in the field of market information value-added services and media communication and marketing services in China's pharmaceutical and health industry., The field of professional quality improvement has extremely extensive influence. The "Top 100 Pharmaceutical Industry" is comprehensively evaluated by the company's annual pharmaceutical industry sales revenue, total profit and R & D investment results. On the same day, the "most growing product brand" of Chinese medicine selected by the Southern Institute's media "Pharmaceutical Economic News" was released simultaneously. Spike Pharmaceuticals product Beirunning (Olopatadine Hydrochloride Eye Drops) was selected. (Xu Yuting)
2020
09-01
Company Disclosure 2020 Semi-Annual Report
On August 28, the Group held the 16th meeting of the 10th Board of Directors of the Company by means of communication, and considered and adopted the "2020 Semi-Annual Report of Jianfeng Group" and the "Proposal on Changes in the Company's Accounting Policy". On August 29, the Company's 2020 semi-annual report was publicly disclosed on the Shanghai Stock Exchange and the Shanghai Securities News and China Securities News. In the first half of the year, the Group focused on the general policy of "grasping projects, making up for shortcomings, improving quality and efficiency, and constantly improving the core competitive advantage", and on the basis of doing a good job in epidemic prevention and control, the Group seized the resumption of work and production, accelerated project construction, and enhanced the core competitiveness of enterprises. In the first half of 2020, the company achieved total operating income of 1.44 billion yuan, net profit attributable to shareholders of 0.368 billion yuan, net profit per share of 1.07 yuan. As of the end of June 2020, the Company's total assets were $5.892 billion, net assets were $4.068 billion, and net assets per share were $11.82. From February to April, affected by the epidemic, the national project construction progress slowed down, cement market demand decreased; after May, the epidemic was effectively controlled, infrastructure investment continued to recover, the real estate industry continued to pick up, cement sales steadily rebounded. During the outbreak, Daye Peak completed the technical transformation projects such as the cold machine, cement mill, into the desulfurization tower anti-corrosion transformation, to ensure the efficient operation of the production equipment after the resumption of work. Yunnan peak rotary kiln production, cement production and other major technical and economic indicators of steady rise; comply with market trends, timely adjustment of marketing policies. Guizhou Jianfeng has promoted the project infrastructure construction, equipment installation and commissioning, raw material bidding and other work in an orderly manner, and through preliminary publicity to enhance the popularity of the Jianfeng brand in the local area, and make a series of preparations for the transformation from project construction to production and operation. In the first half of 2020, the reform of China's medical and health system continued to deepen, and new policies were introduced intensively. Peak Pharmaceuticals and its subsidiaries in the epidemic prevention work at the same time in the first time to achieve the resumption of production, and actively organize donations to support the fight against the epidemic, was named the annual "war epidemic star" the most socially responsible pharmaceutical enterprises. In the first half of the year, Jianfeng Pharmaceutical continued to increase the introduction and development of varieties, and JFAN-1001 applied for clinical application of new anti-tumor drugs. At present, it has obtained the notice of approval for clinical trials. Optimize the production process of API workshop and further shorten the production cycle of raw materials. Continue to improve product sales policies and strengthen market channel control. Shanghai North Carolina further straightened out the internal management structure, production and marketing convergence more smoothly, continue to promote the construction of Anhui North Carolina and Anhui Zhongwang Phase II technical transformation project, promote the peak pharmaceutical raw materials, preparations integration of industrial upgrading strategy. Other business segments of the company actively responded to the challenge of the new crown epidemic and carried out production and operation activities in a standardized and orderly manner. Tianjin natural products company vigorously explore the international and domestic markets, sales revenue to achieve steady growth. Peak Health focuses on the basic idea of "sales orientation, burden reduction and efficiency improvement, fine-grained savings, cost reduction and efficiency enhancement" to effectively improve the operational efficiency of enterprises. Jianfeng International Trade has actively developed new storage business varieties and achieved practical results, and has become the first enterprise in Jinhua to formally obtain the qualification of "network freight. Peak cable seizes the special needs of communication cables such as subways, vigorously promotes large logarithmic cables for subways, and strives to achieve the long tail effect. On the same day, the company also held the 10th meeting of the Ninth Board of Supervisors and reviewed and approved relevant reports. (residual fruit)
2020
09-01
The company organizes new employee induction training
From August 12 to 14, in order to strengthen the training of talents in the group and improve the comprehensive quality of new employees, Jiang Xiaomeng, secretary of the party committee and chairman of the group company, Yu Jianhong, general manager, and other leaders and heads of relevant enterprises and departments conducted a three-day induction training for new employees. New employees from foreign enterprises such as Guizhou Huangping Peak, Daye Peak and Shanghai North Carolina participated simultaneously through online methods. In the course of corporate culture, General Manager Yu Jianhong started from the history of the development and struggle of the peak, divided into five stages: hard work, determined reform, diversified development, strategic adjustment, and strategic development, and introduced in detail the development process of the group company and the current industrial layout., The results achieved; from the aspects of enterprise spirit, vision, development philosophy, values, business philosophy, etc, this paper introduces the peak corporate culture rooted in 62 years of history and inherited in the blood; from the perspective of an enterprise manager and old employees, he speaks a lot of truth to the new employees and puts forward a lot of hopes and suggestions. Chairman Jiang Xiaomeng took "How New Employees Achieve Win-Win with Enterprises" as the topic, and proposed that the key to the success of an enterprise lies in how to select, retain, educate and employ people. Peak and employees complement each other. Peak can achieve today's achievements and the struggle of generations of peak people are inseparable. He also taught new employees the basic concepts that need to be understood, the basic qualities that need to be possessed and the sense of hardship in entering the new environment through 16 key words, and combined with his own experience and quoting from others, he analyzed the core elements of success, the signs of a successful career, the personal qualities that need to be possessed for success, and the importance of establishing a personal knowledge management system, it expresses the ardent hope of new employees to adjust their mentality, keep learning, clear goals, clear dreams, cultivate win-win thinking, and grow up together with the peak. The heads of the human resources department of the group company, the safety management office of the group company, and the comprehensive department of the pharmaceutical company also taught the new employees the corporate rules and regulations and the "Employee Handbook", safety knowledge and professional ethics. The new employees also visited the group exhibition hall and had a deeper understanding of the development history and enterprise achievements of the peak. After the training, the human resources department also organized an examination to test the training effect. (Reporter Chen Shengmu)
2020
08-21
According to this newspaper, through the interconnection monitoring of the transportation department in Zhejiang province, the network freight platform of peak international trading company passed the online service capability audit, interface access audit, eight capability identification and other audit procedures, and successfully obtained the road transportation business license with the qualification of "network freight" on July 2. It is understood that Jianfeng International Trade is currently the first enterprise in Jinhua and Quzhou to obtain this qualification.
2020
08-05
News from our newspaper On July 21, Xi Jinping, General Secretary of the Central Committee of the Communist Party of China, President of the State, and Chairman of the Central Military Commission hosted a symposium for entrepreneurs in Beijing and delivered an important speech. Over the past few days, the General Secretary's speech has aroused strong repercussions in all walks of life. On July 23, Jiang Xiaomeng, chairman of the group company, said in an interview with Jinhua TV that the general secretary's speech was calm and inspiring, and pointed out the direction of future work for entrepreneurs.
2020
08-05